



ARTICLE

Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in *DYRK1A*

Lucas M Bronicki^{*,1,16}, Claire Redin^{2,16}, Severine Drunat³, Amélie Piton^{2,4}, Michael Lyons¹, Sandrine Passemard³, Clarisse Baumann⁵, Laurence Faivre^{6,7,8}, Julien Thevenon^{6,7,8}, Jean-Baptiste Rivière^{6,8,9}, Bertrand Isidor¹⁰, Grace Gan², Christine Francannet¹¹, Marjolaine Willems¹², Murat Gunel¹³, Julie R Jones¹, Joseph G Gleeson¹⁴, Jean-Louis Mandel^{2,4}, Roger E Stevenson¹, Michael J Friez¹ and Arthur S Aylsworth¹⁵

The dual-specificity tyrosine-phosphorylation-regulated kinase 1A (*DYRK1A*) gene, located on chromosome 21q22.13 within the Down syndrome critical region, has been implicated in syndromic intellectual disability associated with Down syndrome and autism. *DYRK1A* has a critical role in brain growth and development primarily by regulating cell proliferation, neurogenesis, neuronal plasticity and survival. Several patients have been reported with chromosome 21 aberrations such as partial monosomy, involving multiple genes including *DYRK1A*. In addition, seven other individuals have been described with chromosomal rearrangements, intragenic deletions or truncating mutations that disrupt specifically *DYRK1A*. Most of these patients have microcephaly and all have significant intellectual disability. In the present study, we report 10 unrelated individuals with *DYRK1A*-associated intellectual disability (ID) who display a recurrent pattern of clinical manifestations including primary or acquired microcephaly, ID ranging from mild to severe, speech delay or absence, seizures, autism, motor delay, deep-set eyes, poor feeding and poor weight gain. We identified unique truncating and non-synonymous mutations (three nonsense, four frameshift and two missense) in *DYRK1A* in nine patients and a large chromosomal deletion that encompassed *DYRK1A* in one patient. On the basis of increasing identification of mutations in *DYRK1A*, we suggest that this gene be considered potentially causative in patients presenting with ID, primary or acquired microcephaly, feeding problems and absent or delayed speech with or without seizures.

European Journal of Human Genetics (2015) **23**, 1482–1487; doi:10.1038/ejhg.2015.29; published online 29 April 2015

INTRODUCTION

Intellectual disability (ID) is clinically defined by the childhood onset (prior to age 18) of impaired cognitive functioning (intelligence quotient (IQ) below 70) and limited adaptive skills and behaviors. The causes of ID are heterogeneous and complex, with both environmental and genetic factors well recognized. Most known causes of severe ID are genetic, with about 25% of cases resulting from monogenic anomalies, copy-number variants and chromosomal abnormalities.^{1,2} Efforts to identify causative genes implicated in monogenic forms of ID have produced multiple candidates, with a significant proportion of these genes (>100) mapping to the X chromosome.^{3–5} In recent years, the implementation of high-throughput technologies, such as next-generation sequencing (NGS), array comparative genomic hybridization and single-nucleotide

polymorphism (SNP) arrays, has facilitated and expedited the discovery of numerous genes that cause or contribute to various forms of ID.^{6,7}

Out of the autosomal genes known to have a role in severe ID, the dual-specificity tyrosine-phosphorylation-regulated kinase (*DYRK1A*) gene (OMIM 600855) has been one of the most extensively studied.^{8–11} Interest in *DYRK1A* originated because of its genomic localization within the Down syndrome critical region (DSCR) on chromosome 21q22, a chromosomal region that is presumed to be largely responsible for the neuropathologic abnormalities observed in Down syndrome.¹² *DYRK1A* exhibits an extraordinarily high degree of protein sequence conservation in animals across all vertebrates,¹³ and animal models have been instrumental in determining the functions of the encoded proline-directed serine/threonine kinase. Some of the

¹Greenwood Genetic Center, Greenwood, SC, USA; ²Department of Translational Medicine and Neurogenetics, IGBMC, CNRS UMR 7104, INSERM U964, Strasbourg University, Strasbourg, France; ³Department of Genetics and INSERM U1141, Robert Debré Hospital, Paris, France; ⁴Laboratoire de diagnostic génétique, Faculty of Medicine and CHU Strasbourg, Strasbourg, France; ⁵Department of Genetics, Robert Debré Hospital, Paris, France; ⁶Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (TRANSLAD), Centre Hospitalier Universitaire Dijon, Dijon, France; ⁷Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs de l'Interrégion Est, Centre Hospitalier Universitaire Dijon, Dijon, France; ⁸Equipe d'Accueil 4271, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon, France; ⁹Laboratoire de Génétique Moléculaire, Plateau Technique de Biologie, Centre Hospitalier Universitaire Dijon, Dijon, France; ¹⁰Medical Genetics-Clinical Genetics Unit, CHU de Nantes, Nantes-Cedex, France; ¹¹Service de génétique médicale, CHU de Clermont-Ferrand, Clermont-Ferrand, France; ¹²Department of Medical Genetics, Reference Center for Rare Diseases, Developmental Disorders and Multiple Congenital Anomalies, Arnaud de Villeneuve Hospital, Montpellier, France; ¹³Department of Genetics and Neurosurgery, Yale University School of Medicine, New Haven, CT, USA; ¹⁴Department of Neurosciences, Howard Hughes Medical Institute, Rady Children's Hospital, University of California, San Diego, La Jolla, CA, USA; ¹⁵Departments of Pediatrics and Genetics, Division of Genetics and Metabolism, University of North Carolina, Chapel Hill, NC, USA

*Correspondence: Dr LM Bronicki, Molecular genetics, Greenwood Genetic Center, 101 Gregor Mendel Circle, Greenwood, SC 29646, USA. Tel: +1 8643881725; Fax: +1 8649418141; E-mail: lbronicki@ggc.org

¹⁶These authors contributed equally to this work.

Received 12 September 2014; revised 18 December 2014; accepted 28 January 2015; published online 29 April 2015

well-delineated roles of DYRK1A are in neuronal development, particularly in regulating neuronal proliferation, differentiation, plasticity and death.^{14–17} *Drosophila* mutants lacking the DYRK1A ortholog minibrain (*mbm*) have reduced brain size and abnormalities of olfaction and vision.¹⁸ DYRK1A haploinsufficiency in mice results in a smaller brain size, developmental delay,¹⁹ decreased motor function,²⁰ cognitive impairment and adverse stress coping behavior.²¹

Patients with partial monosomy 21 or rearrangements that involve DYRK1A and other contiguous genes have been described with phenotypes similar to the ones found in DYRK1A ortholog-deficient animal models including microcephaly, ID and developmental delay.^{22–26} Seven previously reported patients with chromosomal rearrangements, microdeletions or truncating mutations that disrupted specifically DYRK1A had ID, microcephaly, speech delay/absence and feeding dysfunction.^{22,25,27–31} Here, we describe an additional 10 unrelated patients with mutations involving DYRK1A, and further delineate a recurrent pattern of clinical features.

SUBJECTS AND METHODS

Most probands had been previously evaluated with extensive single gene testing, karyotyping, microarray analysis and/or metabolic testing.

Whole-exome sequencing was performed on peripheral blood DNA from patients #1 and #4. The Agilent SureSelect All Exome 50 Mb kit (Agilent Technologies, Santa Clara, CA, USA) was used to capture exomes, and sequences were generated using the Illumina HiSeq 2000 platform (San Diego, CA, USA). Reads were aligned to the February 2009 human reference sequence (GRCh37/hg19) using the NextGENe software (Softgenetics, LLC State College, PA), which was also used to call and annotate small insertions/deletions and SNPs. The resulting variants were filtered to exclude common variants (frequency >5%) present in dbSNP (v.137,³² 1000 Genomes Phase I (v3.20101123)³³), ESP-6500 (v.0.0.14; Exome Variant Server, NHLBI GO Exome Sequencing Project, Seattle, WA, USA; <http://evs.gs.washington.edu/EVS/>) and an in-house database using the Cartagenia Bench lab NGS platform (Cartagenia N.V., Leuven, Belgium). We prioritized non-synonymous variants with respect to *in silico* prediction scores obtained from PolyPhen-2,³⁴ SIFT³⁵ and Mutation Taster.³⁶

DYRK1A mutations in patients #2, #3 and #10 were identified using targeted sequencing of coding regions of 217 genes associated with ID or autism. DNA library preparation, enrichment (SureSelect, Agilent Technologies, Santa Clara, CA, USA) and sequencing (HiSeq2500, Illumina) were performed as previously described.³⁷ Pedigree concordance was checked using highly polymorphic microsatellite markers (PowerPlex 16 HS System, Promega, Madison, WI, USA).

For patient #5, a custom NGS target enrichment system (Agilent SureSelect, Agilent Technologies, Santa Clara, CA, USA) was used to enrich coding and flanking intronic regions of 92 autosomal and X-linked genes known for their association with autism spectrum disorders. A DNA library was prepared using the Fragment Library Preparation 5500 Series SOLiD Systems (Agilent Technologies, Santa Clara, CA, USA) and loaded onto the Applied Biosystems SOLiD 5500×1 platform (Life Technologies, Carlsbad, CA, USA), as per the manufacturer's instructions. Alignment of reads, variant calling, annotating and filtering strategies were performed similarly to those for patients #1 and #4.

Comparative genomic hybridization and SNP oligonucleotide array (CGH+SNP 180 K, Agilent Technologies, Santa Clara, CA, USA) were used to identify the deletion in patient #6. The deletion was confirmed by quantitative real-time polymerase chain reaction (PCR) analysis using SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) with two independent pairs of primers targeting DYRK1A. Relative quantification was performed on a 7900HT Sequence detection system (Applied Biosystems, Life Technologies). Two internal reference sequences were used for normalization.

For patients #7 and #8, mutations in DYRK1A were identified by targeted NGS of 24 genes included in a panel designed for the molecular diagnosis of primary microcephalies. NGS of libraries was performed on a MiSeq platform (Illumina) after multiplex PCR enrichment on a microfluidic Access Array

support (Fluidigm, San Francisco, CA, USA). Genetic variation annotation was performed with the IntegraGen in-house pipeline (IntegraGen, Evry, France).

For patient #9, whole-exome capture and sequencing were performed at Integragen (Evry, France) using the SureSelect Human All Exon V5 kit (Agilent Technologies, Santa Clara, CA, USA). The resulting libraries were sequenced on a HiSeq 2000 (Illumina) according to the manufacturer's recommendations for paired-end 76 bp reads. Over 4.8 Gbs of mappable sequences were generated per individual, resulting in a depth of coverage >10X for more than 92.8% of RefSeq-coding exons. Reads were aligned to the human genome reference sequence (GRCh37/hg19) with the Burrows–Wheeler Aligner (BWA, v0.6.2),³⁸ and potential duplicate paired-end reads were marked using Picard 1.77 (<http://broadinstitute.github.io/picard/>). The Genome Analysis Toolkit (GATK) 2.6–4³⁹ was used for base quality score recalibration, indel realignment and variant discovery (both single-nucleotide variants and indels). Variants were annotated with SeattleSeq SNP Annotation. Rare variants were identified by focusing on protein-altering and splice-site changes present at a frequency below 1% in dbSNP 138 and the NHLBI GO Exome Sequencing Project, and absent from 70 local exomes of unaffected individuals.

All detected mutations and structural variants are described in accordance with the HGVS (Human Genome Variation Society) nomenclature guidelines, and are reported in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) as 'pathogenic' or 'likely pathogenic' (Table 2). Exon numbering was performed using systematic numbering (as opposed to legacy numbering), numbering the first exon of the respective DYRK1A transcript NM_001396.3 as 1, as recommended.⁴⁰

RESULTS

The clinical findings in all 10 patients are summarized in Table 1 and more details are available in Supplementary Data S1. Seven of the patients were male. At last examination, patients' ages ranged from 2 to 32 years.

Some invariable features were reported in all 10 patients, including intellectual disability, absent/severely limited speech and primary or acquired microcephaly (defined as head circumference two or more standard deviations below the mean for age).⁴¹ Developmental milestones were globally delayed, with independent walking achieved after 18 months and initial words after 18 months in those who acquired speech. Intellectual disability was severe in most cases. Autism was diagnosed in four patients. Seizures were reported in eight patients.

Microcephaly was congenital in 5/10 patients and developed postnatally in the other 5. However, patient #9 with initial congenital microcephaly was found to be normocephalic at her last physical assessment. Other craniofacial findings were frequent, including thin upper lip in 9/10 patients, micrognathia (7/10), large, low-set or malformed ears (6/10), long and flat philtrum (5/10), narrow and pointed nasal tip (5/10) and sparse hair (2/10). Representative facial photographs are shown in Figure 1. In addition to microcephaly, a general tendency of poor pre- and/or postnatal growth was observed in some patients, with either low birth weight (<–2 SD, three patients), poor weight gain (<–2 SD, five patients) and/or short stature (<–2 SD, two patients). Interestingly, a severe feeding disorder seems to be a prominent feature (9/10 patients), which would explain the observed problems with weight gain.

Vision abnormalities (hyperopia, myopia and exotropia) were found in 6/10 patients, with hyperopia being most common. Lastly, an apparent proneness to infections, generally of respiratory nature and limited to early childhood years, was reported in 4/10 patients.

For 9 of the 10 patients tested (#7's parental samples were unavailable), the mutations occurred *de novo* (see Table 2). Seven patients were found to harbor heterozygous frameshift or nonsense mutations, localized between exons 5 and 9, of DYRK1A (Table 2 and Figure 2). Two of our ten cases (patients #4 and #9) had heterozygous, non-synonymous, missense mutations. One of these (c.1036T>C, p. Ser346Pro) affects a highly conserved residue (including in

Table 1 Clinical features of patients with *DYRK1A*-associated ID

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Literature cases ^a	Total
Sex	M	M	M	M	M	M	F	M	F	F	3M+4F	10M+9F
Age in years ^b	11	15	4	3.5	6	3.5	6.5	3	32	5	2–20	2–32
Low birth weight	o	+	o	o	o	o	o	o	+	+	3/4	6/14
Weight <3rd centile ^b	o	+	o	+	+	+	o	o	+	+	4/4	9/14
Height <3rd centile ^b	o	o	o	+	o	o	o	o	+	o	4/4	6/14
Microcephaly ^c	+	+	+	+	+	+	+	+	+	+	6/7	16/17
Intellectual disability	+	+	+	+	+	+	+	+	+	+	7/7	17/17
Autism	+	o	o	+	+	o	o	o	+	o	4/4	8/14
Seizures	+	o	o	+	+	+	+	+	+	+	6/6	14/16
Brain MRI	EV and HCC	o	Mildly EV	o	Mildly EV	o	TON	EV	N/A	EV and CA	HCC, CMA, EV	
Speech delay/absence	+	+	+	+	+	+	+	+	+	+	7/7	17/17
Feeding problem	+	+	+	+	+	+	+	+	o	+	5/5	14/15
Deep-set eyes	+	+	+	+	+	+	+	+	+	+	2/4	12/14
Hypermetropia/ myopia	+	+	+	+	+	+	o	N/A	N/A	o	1/1	7/9
Large/dysplastic ears	o	+	o	+	+	o	+	+	o	+	4/5	10/15
Pointed nasal tip	+	+	+	+	o	o	o	+	N/A	+	2/4	8/13
Long/flat philtrum	o	+	+	+	+	o	o	+	o	o	2/2	7/12
Thin upper lip	+	+	+	+	+	+	+	+	+	+	3/5	13/15
Micrognathia	+	+	+	+	+	+	o	+	+	+	1/4	10/14
Stereotypies	+	o	+	+	+	+	o	+	+	+	4/5	12/15
Clumsy/ incoordination	+	o	N/A	o	+	+	+	o	+	+	3/3	9/12
Prone to infections	+	N/A	o	+	+	o	+	o	o	o	4/4	8/13

Abbreviations: CA, cerebellar atrophy; CMA, cortical and medullar atrophy; EV, enlarged ventricles; F, female; HCC, hypoplastic corpus colosum; M, male; MRI, magnetic resonance imaging; N/A, not available; o, absent at last examination; TON, thin optic nerves; +, present at last examination.

^aPatients with mutations affecting specifically *DYRK1A*.

^bAt last clinical assessment.

^cAt birth or last clinical assessment.

invertebrates) located within the protein catalytic domain and is predicted to be deleterious by three prediction software programs (Mutation Taster: 0.99, Sift: 0 and Polyphen2 HumDiv: 1). The other missense mutation (c.1763C>A, p.Thr588Asn) affects a residue located in the more distal C-terminal portion. This residue is conserved across vertebrates and is predicted to be deleterious by two out of three prediction software programs (Mutation Taster: 0.99 and Polyphen2 HumDiv: 0.9; Sift: 0.21, ie tolerated).

Patient #6 from this study has a heterozygous 1.7 Mb interstitial deletion that includes *DYRK1A* and an additional 11 genes (*SIM2*, *HLCS*, *RIPPLY3*, *PIGP*, *TTC3*, *DSCR3*, *KCNJ6*, *DSCR4*, *DSCR8*, *KCNJ15* and 3' end of *ERG*; see Table 2). Heterozygous deletion of these other 11 genes did not appear to increase the severity of this patient's phenotype.

Overall, no specific genotype-to-phenotype correlation could be drawn from these patients. For example, patients with missense mutations or truncating mutations near the terminal end of the gene did not present with milder phenotypes as compared with patients harboring early-truncating *DYRK1A* mutations or large deletions encompassing several genes.

DISCUSSION

DYRK1A has received attention in the past decade because of its association with early-onset cognitive impairment resulting from complete or partial duplication/deletion of chromosome 21. Here, we report 10 novel patients with mutations affecting *DYRK1A*, compare them with those previously described and highlight recurrent clinical manifestations in those patients.

Remarkably, all patients with *DYRK1A*-associated ID from this and previous studies present with similar clinical manifestations, regardless of the type of mutation affecting *DYRK1A* function. This study expands the

spectrum of genetic aberrations affecting the *DYRK1A* locus that have been described to date, which now includes large deletions, chromosomal translocations and truncating and missense point mutations.

Given the locations of the observed missense mutations along with the associated patients' phenotypes (eg similar to patients carrying null mutations), it is likely that these are loss-of-function mutations that alter protein folding and/or the protein's kinase activity.^{42,43} The truncating mutations described in this study presumably promote nonsense-mediated decay of the *DYRK1A* mRNA. All point mutations (non-synonymous and truncating mutations) affect residues widespread within the protein, located either in the *DYRK1A*-protein catalytic domain or the *DYRK1A*-C-terminal portion.

There are a number of reported cases with large deletions or chromosomal translocations disrupting the *DYRK1A* locus.^{22–26} Most of these patients exhibited a constellation of phenotypes with variable severity, which could be explained by the deletion of additional genes from 21q or imbalances in other regions of the genome. For example, two previously reported cases have chromosomal translocations with breakpoints within *DYRK1A*.²² Although these two patients shared many similar clinical features, such as microcephaly and feeding difficulties, one of them was more severely affected with more severe developmental delay, features attributed to a chromosomal breakpoint within the *LRP1B* gene and duplication of a region at Xp22 including the *GEMIN8* gene. In our study, a microdeletion of *DYRK1A* and surrounding genes did not seem to influence the severity of the patient's (#6) phenotype, providing further evidence that *DYRK1A* is the primary gene within the *DSCR* that is responsible for the clinical features reported in patients with *DYRK1A*-associated ID.

Despite the phenotypic variability apparent in patients with *DYRK1A*-associated ID, there are five cardinal clinical features that are found almost universally among patients with *DYRK1A* mutations.




Figure 1 Pictures of seven patients with *DYRK1A*-associated ID described in this study. Note the common clinical features among most of the patients, including microcephaly, deep-set eyes, protruding ears, long and flat philtrum with thin upper vermillion and micrognathia. The corresponding patient numbers are as follows: (a) #1, (b) #2, (c) #3, (d) #4, (e) #5, (f) #9 and (g) #10.

Table 2 Types of *DYRK1A* mutations identified in the present study

Patient	Type of mutation	Nomenclature ^a	Inheritance	ClinVar accession number
1	Nonsense	c.763C>T, p.Arg255 ^a	<i>De novo</i>	SCV000196057
2	Nonsense	c.613C>T, p.Arg205 ^a	<i>De novo</i>	SCV000196058
3	Frameshift	c.621_624delinsGAA, p.Glu208Asnfs*3	<i>De novo</i>	SCV000196059
4	Missense	c.1036T>C, p.Ser346Pro	<i>De novo</i>	SCV000196060
5	Frameshift	c.945dupG, p.Gln316Alafs*24	<i>De novo</i>	SCV000196061
6	1.7 Mb deletion	chr21.hg19:g.(?_38007970)_ (39747620_?)del	<i>De novo</i>	SCV000196062
7	Nonsense	c.1309C>T, p.Arg437 ^a	Parent samples not available	SCV000196063
8	Frameshift	c.844dupA, p.Ser282Lysfs*6	<i>De novo</i>	SCV000196064
9	Missense	c.1763C>A, p.Thr588Asn	<i>De novo</i>	SCV000196065
10	Frameshift	c.1232dupG, p.Arg413Thrfs*10	<i>De novo</i>	SCV000196066

^aUsing NCBI reference sequence NM_001396.3.




Figure 2 Schematic depicting the approximate locations of all the truncating and missense mutations, deletions and chromosomal rearrangements affecting *DYRK1A* (NM_001396.3). Truncating and missense mutations (gray stars), translocation breakpoints (lightning symbols) and microdeletions (rectangles) of the previously published cases with *DYRK1A* syndrome. Black-colored stars represent the approximate location of mutation sites within the *DYRK1A* locus of patients presented in this paper. Idiogram of human chromosome 21 (GRCh37/hg19 assembly) was obtained from the UCSC genome browser website.⁵²

These include moderate-to-severe ID (100%), absent or delayed speech (100%), primary or acquired microcephaly (94.1%), feeding issues (93.3%) and seizures (87.5%). The prevalent appearance of these clinical features supports the essential roles of *DYRK1A* in brain development and function. *DYRK1A* has been shown to positively regulate brain size by controlling neuronal precursor proliferation, neuronal differentiation and synaptogenesis and survival, particularly in the optic lobes, superior colliculus, central brain hemispheres and hippocampus.^{18,19,21,44,45} The reduced brain size may be partially explained by the dual role of *DYRK1A* in inhibiting the proliferation of neuronal progenitors via suppression of NOTCH signaling and Cyclin D1 while also promoting neurogenesis by stabilizing the cyclin-dependent kinase inhibitor p27^(KIP1).^{46,47} In addition, *DYRK1A* interacts with the microtubule and actin cytoskeletal networks to regulate neurite outgrowth and synaptogenesis.^{48–50} Through these mechanisms, haploinsufficiency of *DYRK1A* presumably leads to augmented neuronal precursor proliferation and apoptosis, decreased neurogenesis and abnormal neuritogenesis. A molecular mechanism that may explain the suppressed appetite in patients with *DYRK1A*-associated ID has recently been elucidated in flies and mice. *Dyrk1A* is part of a positive feedback loop that regulates neuropeptide Y levels and consequently food intake.⁵¹

Although many of the five principal clinical features found in patients with *DYRK1A* defects are also typically present in a number of other monogenic (eg Rett, Christianson and FOXP1 syndromes) and chromosomal disorders (eg 1p36 deletion syndrome), patients with *DYRK1A*-associated ID can be distinguished based on other commonly observed manifestations. Often these patients also present with thin upper lip vermilion border (86.7%), deep-set eyes with somewhat full/hooded upper lids (85.7%), stereotypies (80%), hyperopia/myopia (77.8%), clumsy or incoordinated movement (75%), and micrognathia (71.4%). The appearance around the eyes and noses of some cases is reminiscent of the velocardiofacial syndrome due to microdeletion at 22q11.2. (Figure 1, cases D, E and G)

In conclusion, this study describes nine unrelated patients with disease-causing point mutations in *DYRK1A*, and one with similar

phenotypic features caused by a microdeletion involving this gene. Together with previously described cases, these findings produce a more detailed picture of the recurring phenotype and types of mutations in patients with *DYRK1A*-associated ID. Given the increasing frequency of identification of mutations in *DYRK1A*, we suggest that this gene be considered potentially causative in patients presenting with intellectual disability, primary or acquired microcephaly, feeding problems and absent or delayed speech with or without seizures.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

The authors thank the parents for consenting to the clinical and molecular studies and presentation of these findings. The authors also thank the international consortium of clinical and laboratory personnel involved in carrying out these studies. Partial support was provided by the South Carolina Department of Disability and Special Needs and the Greenwood Genetic Center Foundation, and by grants from Fondation Jerome Lejeune, Agence de Biomedecine and CREGEMES to the Strasbourg team.

- 1 van Bokhoven H: Genetic and epigenetic networks in intellectual disabilities. *Annu Rev Genet* 2011; **45**: 81–104.
- 2 Srivastava AK, Schwartz CE: Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms. *Neurosci Biobehav Rev* 2014; **46**: 161–174.
- 3 Lubs HA, Stevenson RE, Schwartz CE: Fragile X and X-linked intellectual disability: four decades of discovery. *Am J Hum Genet* 2012; **90**: 579–590.
- 4 Bassani S, Zapata J, Gerosa L, Moretto E, Murru L, Passafaro M: The neurobiology of X-linked intellectual disability. *Neuroscientist* 2013; **19**: 541–552.
- 5 Piton A, Redin C, Mandel JL: XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. *Am J Hum Genet* 2013; **93**: 368–383.
- 6 Gilissen C, Hehir-Kwa JY, Thung DT *et al*: Genome sequencing identifies major causes of severe intellectual disability. *Nature* 2014; **511**: 344–347.
- 7 Henderson LB, Applegate CD, Wohler E, Sheridan MB, Hoover-Fong J, Batista DA: The impact of chromosomal microarray on clinical management: a retrospective analysis. *Genet Med* 2014; **16**: 657–664.
- 8 Becker W, Sippl W: Activation, regulation, and inhibition of *DYRK1A*. *FEBS J* 2011; **278**: 246–256.

- 9 Tejedor FJ, Hammerle B: MNB/DYRK1A as a multiple regulator of neuronal development. *FEBS J* 2011; **278**: 223–235.
- 10 Wegiel J, Gong CX, Hwang YW: The role of DYRK1A in neurodegenerative diseases. *FEBS J* 2011; **278**: 236–245.
- 11 Park J, Chung KC: New perspectives of Dyrk1A role in neurogenesis and neuropathologic features of Down syndrome. *Exp Neurol* 2013; **22**: 244–248.
- 12 Guimera J, Casas C, Pucharcos C *et al*: A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. *Hum Mol Genet* 1996; **5**: 1305–1310.
- 13 Galceran J, de Graaf K, Tejedor FJ, Becker W: The MNB/DYRK1A protein kinase: genetic and biochemical properties. *J Neural Transm Suppl* 2003; 139–148.
- 14 Hammerle B, Elizalde C, Tejedor FJ: The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. *Eur J Neurosci* 2008; **27**: 1061–1074.
- 15 Fernandez-Martinez J, Vela EM, Tora-Ponsioen M, Ocana OH, Nieto MA, Galceran J: Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. *J Cell Sci* 2009; **122**: 1574–1583.
- 16 Murakami N, Bolton DC, Kida E, Xie W, Hwang YW: Phosphorylation by Dyrk1A of clathrin coated vesicle-associated proteins: identification of the substrate proteins and the effects of phosphorylation. *PLoS One* 2012; **7**: e34845.
- 17 Barallobre MJ, Perier C, Bove J *et al*: DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease. *Cell Death Dis* 2014; **5**: e1289.
- 18 Tejedor F, Zhu XR, Kaltenbach E *et al*: Minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. *Neuron* 1995; **14**: 287–301.
- 19 Fotaki V, Dierssen M, Alcantara S *et al*: Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. *Mol Cell Biol* 2002; **22**: 6636–6647.
- 20 Fotaki V, Martinez De Lagran M, Estivill X, Arbones M, Dierssen M: Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. *Behav Neurosci* 2004; **118**: 815–821.
- 21 Arque G, Fotaki V, Fernandez D, Martinez de Lagran M, Arbones ML, Dierssen M: Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). *PLoS One* 2008; **3**: e2575.
- 22 Moller RS, Kubart S, Hoeltzenbein M *et al*: Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. *Am J Hum Genet* 2008; **82**: 1165–1170.
- 23 Oegema R, de Klein A, Verkerk AJ *et al*: Distinctive phenotypic abnormalities associated with submicroscopic 21q22 deletion including DYRK1A. *Mol Syndromol* 2010; **1**: 113–120.
- 24 Fujita H, Torii C, Kosaki R *et al*: Microdeletion of the Down syndrome critical region at 21q22. *Am J Med Genet A* 2010; **152A**: 950–953.
- 25 Yamamoto T, Shimojima K, Nishizawa T, Matsuo M, Ito M, Imai K: Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6. *Am J Med Genet A* 2011; **155A**: 113–119.
- 26 Valetto A, Orsini A, Bertini V *et al*: Molecular cytogenetic characterization of an interstitial deletion of chromosome 21 (21q22.13q22.3) in a patient with dysmorphic features, intellectual disability and severe generalized epilepsy. *Eur J Med Genet* 2012; **55**: 362–366.
- 27 van Bon BW, Hoischen A, Hehir-Kwa J *et al*: Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. *Clin Genet* 2011; **79**: 296–299.
- 28 Courcet JB, Faivre L, Malzac P *et al*: The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. *J Med Genet* 2012; **49**: 731–736.
- 29 O'Roak BJ, Vives L, Fu W *et al*: Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science* 2012; **338**: 1619–1622.
- 30 O'Roak BJ, Vives L, Girirajan S *et al*: Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* 2012; **485**: 246–250.
- 31 Iossifov I, Ronemus M, Levy D *et al*: De novo gene disruptions in children on the autistic spectrum. *Neuron* 2012; **74**: 285–299.
- 32 Sherry ST, Ward MH, Kholodov M *et al*: dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* 2001; **29**: 308–311.
- 33 1000 Genomes Project Consortium, Abecasis GR, Altshuler D *et al*: A map of human genome variation from population-scale sequencing. *Nature* 2010; **467**: 1061–1073.
- 34 Adzhubei IA, Schmidt S, Peshkin L *et al*: A method and server for predicting damaging missense mutations. *Nat Methods* 2010; **7**: 248–249.
- 35 Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 2009; **4**: 1073–1081.
- 36 Schwarz JM, Rodelsperger C, Schuelke M, Seelow D: MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods* 2010; **7**: 575–576.
- 37 Redin C, Le Gras S, Mhamdi O *et al*: Targeted high-throughput sequencing for diagnosis of genetically heterogeneous diseases: efficient mutation detection in Bardet-Biedl and Alstrom syndromes. *J Med Genet* 2012; **49**: 502–512.
- 38 Li H, Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler Transform. *Bioinformatics* 2010; **26**: 589–595.
- 39 McKenna A, Hanna M, Banks E *et al*: The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**: 1297–1303.
- 40 Dagleish R, Flicke P, Cunningham F *et al*: Locus Reference Genomic sequences: an improved basis for describing human DNA variants. *Genome Med* 2010; **2**: 24.
- 41 Ashwal S, Michelson D, Plawner L, Dobyns WB: Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2009; **73**: 887–897.
- 42 Himpel S, Panzer P, Eirmbter K *et al*: Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. *Biochem J* 2001; **359**: 497–505.
- 43 Wiechmann S, Czajkowska H, de Graaf K, Grotzinger J, Joost HG, Becker W: Unusual function of the activation loop in the protein kinase DYRK1A. *Biochem Biophys Res Commun* 2003; **302**: 403–408.
- 44 Benavides-Piccione R, Dierssen M, Ballesteros-Yanez I *et al*: Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A^{+/-} mouse. *Neurobiol Dis* 2005; **20**: 115–122.
- 45 Guo X, Williams JG, Schug TT, Li X: DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. *J Biol Chem* 2010; **285**: 13223–13232.
- 46 Hammerle B, Ulin E, Guimera J, Becker W, Guillemot F, Tejedor FJ: Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. *Development* 2011; **138**: 2543–2554.
- 47 Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W: The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation. *Cell Cycle* 2014; **13**: 2084–2100.
- 48 Scales TM, Lin S, Kraus M, Goold RG, Gordon-Weeks PR: Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons. *J Cell Sci* 2009; **122**: 2424–2435.
- 49 Martinez de Lagran M, Benavides-Piccione R, Ballesteros-Yanez I *et al*: Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. *Cereb Cortex* 2012; **22**: 2867–2877.
- 50 Dowjat K, Adayev T, Kaczmarek W, Wegiel J, Hwang YW: Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients. *J Neuropathol Exp Neurol* 2012; **71**: 1100–1112.
- 51 Hong SH, Lee KS, Kwak SJ *et al*: Minibrain/Dyrk1a regulates food intake through the Sir2-FOXO-sNPF/NPY pathway in Drosophila and mammals. *PLoS Genet* 2012; **8**: e1002857.
- 52 Kent WJ, Sugnet CW, Furey TS *et al*: The human genome browser at UCSC. *Genome Res* 2002; **12**: 996–1006.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)